How can we recognize "disease modification" effects?

Journal of Nutrition, Health and Aging

Volumn 13, Issue 4, 2009, Pages 341-343

  Siemers, E R ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALZHEIMER DISEASE VACCINE; BAPINEUZUMAB; BIOLOGICAL MARKER; LY 2062430; MONOCLONAL ANTIBODY; N2 [2 (3,5 DIFLUOROPHENYL) 2 HYDROXYACETYL] N1 (6,7 DIHYDRO 5 METHYL 6 OXO 5H DIBENZ[B,D]AZEPIN 7 YL)ALANINAMIDE; SOLANEZUMAB; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ARTICLE; BRAIN ATROPHY; CEREBROSPINAL FLUID ANALYSIS; CLINICAL TRIAL; DIAGNOSTIC PROCEDURE; DISEASE COURSE; DISEASE MARKER; HUMAN; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

ALZHEIMER DISEASE; BIOLOGICAL MARKERS; CLINICAL TRIALS AS TOPIC; HUMANS; TREATMENT OUTCOME;

EID: 65249111508     PISSN: 12797707     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12603-009-0036-7     Document Type: Article

References (33)

1. European Medicines Agency, Committee for Medicinal Products for Human Use. Guideline on medicinal products for the treatment of Alzheimer's disease and other dementias. Doc. Ref. CPMP/EWP/553/95 Rev. 1. London. 24 July 2008.
2. Mobs RC, Kawas C, Carillio M: Perspective: Optimal Design of Clinical Trials for Drugs Designed to Slow the Course of Alzheimer's Disease. Alzheimer's and Dementia 2006;2:131-139.
3. Biomarkers Definitions Working Group, Atkinson AJ, Colburn WA, DeGruttola VG, DeMets DL, Downing GJ, Hoth DF, Oates JA, Peck CC, Schooley RT, Spilker BA, Woodcock J, Zeger SL. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clin Pharmacol Ther 2001;69:89-95.
4. U.S. Department of Health and Human Services, Food and Drug Administration. Critical path opportunities report. Washington, DC, March 2006.
5. Temple R. Are Surrogate Markers Adequate to Assess Cardiovascular Disease Drugs? JAMA 1999;282:790-795.
6. Matthews B, Siemers ER, Mozley PD. Imaging based measures of disease progression in clinical trials of disease modifying drugs for Alzheimer disease. Am J Geriatr Psychiatry 2003;11:146-159.
7. Thal LJ, Kantarci K, Reiman EM, Klunk WE, Weiner MW, Zetterberg H, Galasko D, Praticò D, Griffin S, Schenk D, Siemers E. The Role of Biomarkers in Clinical Trials for Alzheimer's Disease. Alzheimer Dis Assoc Disord 2006;20:6-15.
8. Frank RA, Galasko D, Hampel H, Hardy J, de Leon MJ, Mehta PD, Rogers J, Siemers E, Trojanowski JQ. Biological markers for therapeutic trials in Alzheimer's disease. Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer disease. Neurobiol Aging 2003;24:521-536.
9. Blennow K, Zetterberg H, Minthon L, Lannfelt L, Strid S, Annas P, Basun H, Andreasen N. Longitudinal stability of CSF biomarkers in Alzheimer's disease. Neurosci Lett 2007;419:18-22.
10. Sunderland T, Wolozin B, Galasko D, Levy J, Dukoff R, Bahro M, Lasser R, Motter R, Lehtimäki T, Seubert P. Longitudinal stability of CSF tau levels in Alzheimer patients. Biol Psychiat 1999;46:750-755.
11. Andreasen N, Hesse C, Davidsson P, Minthon L, Wallin A, Winblad B, Vanderstichele H, Vanmechelen E, Blennow K. Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer's disease: differences between early- and late-onset Alzheimer's disease and stability during the course of disease. Arch Neurol 1999;56:673-680.
12. Engler H, Forsberg A, Almkvist O, Blomquist G, Larsson E, Savitcheva I, Wall A, Ringheim A, Langstrom B, Nordberg A. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain 2006;129:2856-2866.
13. Tierney MC, Fisher RH, Lewis AJ, et al. The NINCDS-ADRDA Work Group criteria for the clinical diagnosis of probable Alzheimer's disease: a clinicopathologic study of 57 cases. Neurology 1988;38:359-364.
14. Siemers ER, Paul SM. Commentary on "A roadmap for the prevention of dementia: The inaugural Leon Thal Symposium". Alzheimers Dement 2008;4:171-173.
15. Aizenstein HJ, Nebes RD, Saxton JA, Price JC, Mathis CA, Tsopelas ND, Ziolko SK, James JA, Snitz BE, Houck PR, Bi W, Cohen AD, Lopresti BJ, DeKosky ST, Halligan EM, Klunk WE. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol 2008;65:1509-1517.
16. Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, Eisner L, Kirby L, Boada Rovira M, Forette F, Orgogozo JM for the AN1792(QS-21)-201 Study Team. Clinical effects of A immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005;64:1553-1562.
17. Fox NC, Black RS, Gilman S, Rossor MN, Griffith SG, Jenkins L, Koller M for the AN1792(QS-21)-201 Study Team. Effects of A immunization (AN1792) on MRI measures of cerbral volume in Alzheimer disease. Neurology 2005;64:1563-1572.
18. Siemers E, Skinner M, Dean RA, Gonzales C, Satterwhite J, Farlow M, Ness D, May PC. Safety, tolerability and changes in amyloid concentrations after administration of a -secretase inhibitor in volunteers. Clin Neuropharmacol 2005;28:126-132.
19. Siemers ER, Quinn JF, Kaye J, Farlow MR, Porsteinsson A, Tariot P, Zoulnouni P, Galvin JE, Holtzman DM, Knopman DS, Satterwhite J, Gonzales C, Dean RA, May PC. Effects of a -secretase inhibitor in a randomized study of patients with Alzheimer disease. Neurology 2006;66:602-604.
20. Siemers ER, Dean RA, Friedrich S, Ferguson-Sells L, Gonzales C, Farlow MR, May PC. Safety, tolerability and effects on plasma and cerebrospinal fluid amyloid-following inhibition of -secretase. Clin Neuropharmacol 2007;30:317-325.
21. Fleisher AS, Raman R, Siemers ER, Becerra L, Clark CM, Dean RA, Farlow MR, Galvin JE, Peskind ER, Quinn JF, Sherzai A, Sowell BB, Aisen PS, Thal LJ. Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease. Arch Neurol 2008;65:1031-1038.
22. Bateman RJ. A turnover in human subjects. Alzheimer's and Dementia 2008;4(Suppl 2):T123.
23. Siemers ER, Benson C, Gonzales C, Hansen R, Dean RA, Farlow M, DeMattos R. Safety assessments and biomarker changes following a monoclonal A antibody given to subjects with Alzheimer's Disease. Alzheimer's and Dementia 2006;2(Suppl):S80.
24. Siemers ER, Friedrich S, Dean RA, Sethuraman G, Demattos RB, Jennings D, Tamagnan G, Marek K, Seibyl J. Safety, tolerability and biomarker effects of an A monoclonal antibody administered to patients with Alzheimer's disease. Alzheimer's and Dementia 2008;4(Suppl 2):T774.
25. DeMattos RB, Dean RA, Friedrich S, Sethuraman G, Racke M, Karran EH, Paul SM, Siemers E. Alterations of novel A biomarkars after administration of a monoclonal antibody specific for soluble A. Hot topics presentation, International Conference on Alzheimer's Disease, Chicago, IL, July 30, 2008.
26. Grundman M, Black R. Clinical trials of bapineuzumab, a beta-amyloid-targeted immunotherapy in patients with mild to moderate Alzheimer's disease. Alzheimer's and Dementia 2008;4(Suppl 2):T166.
27. Selkoe DJ. Alzheimer disease: mechanistic understanding predicts novel therapies. Ann Intern Med 2004;140:627-638.
28. Hardy J. Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002;297(5580):353-356.
29. Corder EH, Saunders AM, Strittmatter WJ, Schmechel D, Gaskell P, Small GW, Roses AD, Haines JL, Pericak-Vance MA (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261:921-923.
30. Saunders AM, Strittmatter WJ, Schmechel D, St. George-Hyslop PH, Pericak-Vance MA, Joo SH, Rosi BL, Gusella JF, Crapper-MacLachlan DR, Alberts MJ, Hulette C, Crain B, Goldgaber D, Roses AD. Association of apolipoprotein E allele 4 with late-onset familial and sporadic Alzheimer's disease. Neurology 1993;43:1467-1472.
31. Leber P. Guidelines for the clinical evaluation of anti-dementia drugs. First Draft. Rockville, MD: US Food and Drug Administration, 1990.
32. Thal LJ, Kantarci K, Reiman EM, Klunk WE, Weiner MW, Zetterberg H, Galasko D, Praticò D, Griffin S, Schenk D, Siemers E. The Role of Biomarkers in Clinical Trials for Alzheimer's Disease. Alzheimer's Dis Assoc Disord 2006;20:6-15.
33. Sethuraman G, Siemers E, Tamura R, Offen W, Mohs R. The Design and Analysis of Alzheimer's Disease Trials with a Delayed Start Period. International Society for Clinical Trials Management. Toronto, Canada, October 6, 2008.